Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort from Foundation Fighting Blindness

Foundation Fighting Blindness

Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort

4 minutes Posted Jul 9, 2025 at 7:22 pm.

0:00

4:00

Share at current time

Show notes

The expanded Phase 1/2/3 shortens time to potential FDA approval.